Clinical and Biochemical Marker as a Predictor in the Early Stages of Pregnancy for the Future Development of Preeclampsia: A Prospective Study
Background: One of the most significant pregnancy problems is preeclampsia (PE). There are 8.5 million women worldwide who are affected with PE, which affects 3 to 8% of pregnancies globally. Objective: This study aims to identify the clinical and biochemical marker as a predictor in the early stages of pregnancy for the future development of preeclampsia in pregnant
women of a tertiary care hospital in Bangladesh. Method: A prospective study was carried out among 119 pregnant women in the outpatient Department of obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University, Bangladesh, from June 2005 July 2006. Details and data obtained from medical records section were analyzed. Results: In our study, 119 women were included. Among them PE developed in 10 patients and 109 patients were normotensive. The mean age was 25.48±5.26 vs
25.60±3.89 in control vs PE subjects. At booking the mean SBP were 104.40±10.67 vs 121.50±6.26, mean DBP were 65.73±6.41 vs 68.00±5.87, mean MAP were 77.66±5.28 vs 78.62±6.39, and mean MAP at 3rd trimester was 78.62±6.39 vs 115.00±8.64 in control and PE subjects. The mean systolic blood pressure during third trimester of the study group was 104.40±10.67 in control vs 135.00±11.79 in PE subjects. The mean diastolic blood pressure during 3rd trimester of the study group was 65.73±6.41 in control vs 105.00±7.82 in PE subjects. Mean arterial blood pressure at 3rd trimester of the study group were 78.68±6.39 in control vs 115.00±8.64 in PE. Conclusion: Many biochemical marker of preeclampsia have been recognized in maternal serum. Single estimation of serum uric acid and creatinine levels early in pregnancy are of little value in the prediction of preeclampsia. Early pregnancy levels of serum albumin can be used as predictors of pre eclampsia.
- Biochemical marker,
How to Cite
Copyright (c) 2022 The Insight
This work is licensed under a Creative Commons Attribution 4.0 International License.